首页> 外文期刊>Journal of thrombosis and thrombolysis >Factor V G1691A, Prothrombin G20210A, and Methylenetetrahydrofolate Reductase (MTHFR) C677T Gene Polymorphism in Angiographically Documented Coronary Artery Disease.
【24h】

Factor V G1691A, Prothrombin G20210A, and Methylenetetrahydrofolate Reductase (MTHFR) C677T Gene Polymorphism in Angiographically Documented Coronary Artery Disease.

机译:血管造影记录的冠状动脉疾病中的因子V G1691A,凝血酶原G20210A和亚甲基四氢叶酸还原酶(MTHFR)C677T基因多态性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Single point mutations in the genes coding for factor V [G1691A; Leiden], prothrombin [PRT; G20210A], and methylenetetrahydrofolate reductase [MTHFR, C677T] were shown to be major inherited predisposing factors for venous thromboembolism. However, their contribution in the development of coronary artery disease [CAD] remains controversial. The aim of the study was to examine the association of these mutations in CAD. Methods: A total of 96 patients with angiographically-demonstrated CAD [mean age 55.3 +/- 11.3], and 404 healthy subjects [mean age 50.7 +/- 8.9] were recruited into the study. Fasting plasma homocysteine was determined by HPLC, and genotype analysis was assessed by PCR-RFLP. Results: The carrier frequency of factor V-Leiden (14.6% vs. 15.1%, p = 0.617) and PRT G20210A (3.1% vs. 3.0%; p = 0.936) were similar between patients and controls, respectively. In contrast, the frequency of the MTHFR variant C677T was 71.9% among patients compared with 45.5% in controls ( p < 0.001), ofwhich the T/T genotype was significantly higher among patients (31.3%) than controls (4.5%; p < 0.001). Significantly higher homocysteine levels were seen among T/T genotype in both groups compared to non-T/T carriers ( p < 0.05), and among patients compared with controls (18.47 +/- 3.73 micromol/L vs. 16.28 +/- 4.16 micromol/L). In addition, the coexistence of MTHFR C677T with FV-Leiden was seen in 10.4% of CAD patients compared 6.9% of controls ( p = 0.001). Conclusion: While results from this study clearly demonstrate a strong association of hyperhomocysteinemia and homozygosity of the MTHFR C677T, but not FV-Leiden or PRT G20210A, mutations with confirmed CAD, they also suggest a potential role for factor V-Leiden in MTHFR C677T carriers.
机译:背景:编码因子V [G1691A;莱顿],凝血酶原[PRT; G20210A]和亚甲基四氢叶酸还原酶[MTHFR,C677T]被证明是静脉血栓栓塞的主要遗传易感因素。然而,它们在冠状动脉疾病[CAD]发展中的作用仍存在争议。该研究的目的是检查CAD中这些突变的关联。方法:共纳入96例血管造影证实的CAD [平均年龄55.3 +/- 11.3]和404名健康受试者[平均年龄50.7 +/- 8.9]。通过HPLC确定空腹血浆同型半胱氨酸,并通过PCR-RFLP评估基因型分析。结果:在患者和对照组中,因子V-Leiden的载频(分别为14.6%和15.1%,p = 0.617)和PRT G20210A(分别为3.1%和3.0%; p = 0.936)相似。相反,患者中MTHFR变异体C677T的发生率为71.9%,而对照组中为45.5%(p <0.001),其中患者中的T / T基因型显着高于对照组(31.3%)(4.5%; p < 0.001)。与非T / T携带者相比,两组的T / T基因型中同型半胱氨酸水平显着更高(p <0.05),与对照组相比,患者之间的同型半胱氨酸水平更高(18.47 +/- 3.73 micromol / L vs. 16.28 +/- 4.16微摩尔/升)。此外,在10.4%的CAD患者中发现MTHFR C677T与FV-Leiden共存,而对照组为6.9%(p = 0.001)。结论:尽管这项研究的结果清楚地表明高同型半胱氨酸血症与MTHFR C677T的纯合子密切相关,但与FV-Leiden或PRT G20210A无关,但具有确诊CAD的突变,他们也暗示了V-Leiden因子在MTHFR C677T携带者中的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号